DrugPatentWatch Database Preview
Kai Pharms Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for KAI PHARMS INC, and what generic alternatives to KAI PHARMS INC drugs are available?
KAI PHARMS INC has one approved drug.
There are six US patents protecting KAI PHARMS INC drugs.
There are seventy-six patent family members on KAI PHARMS INC drugs in forty-one countries and thirteen supplementary protection certificates in twelve countries.
Summary for Kai Pharms Inc
| International Patents: | 76 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Kai Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-001 | Feb 7, 2017 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | 9,701,712 | Start Trial | Y | Y | Start Trial | ||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-002 | Feb 7, 2017 | RX | Yes | Yes | 9,701,712 | Start Trial | Y | Y | Start Trial | ||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-002 | Feb 7, 2017 | RX | Yes | Yes | 8,377,880 | Start Trial | Y | Y | Start Trial | ||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | 8,999,932 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Kai Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2459208 | Start Trial |
| China | 105764487 | Start Trial |
| China | 102711789 | Start Trial |
| Spain | 2607954 | Start Trial |
| Israel | 243210 | Start Trial |
| Portugal | 3013318 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Kai Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2459208 | LUC00008 | Luxembourg | Start Trial | PRODUCT NAME: ETELCALCETIDE, OU UN SEL EQUIVALENT, Y COMPRIS LE CHLORHYDRATE D'ETELCALCETIDE (PARSABIV); AUTHORISATION NUMBER AND DATE: EU/1/16/1142 20161115 |
| 2459208 | 1790012-7 | Sweden | Start Trial | PRODUCT NAME: ETELCALCETIDE, OR SALT THEREOF, INCLUDING ETELCALCETIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/16/1142/001-012 20161115 |
| 2459208 | 132017000041085 | Italy | Start Trial | PRODUCT NAME: ETELCALCETIDE, O UN SUO SALE, COMPRESO ETELCALCETIDE IDROCLORURO(PARSABIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1142/001-012, 20161115 |
| 2459208 | PA2017007 | Lithuania | Start Trial | PRODUCT NAME: ETELKALCETIDAS ARBA JO DRUSKA, ISKAITANT ETELKALCETIDO HIDROCHLORIDA; REGISTRATION NO/DATE: EU/1/16/1142 20161111 |
| 2459208 | C20170006 00208 | Estonia | Start Trial | PRODUCT NAME: ETELKALTSETIID;REG NO/DATE: EU/1/16/1142 15.11.2016 |
| 2459208 | 122017000021 | Germany | Start Trial | PRODUCT NAME: ETELCALCETID ODER EIN SALZ DAVON, EINSCHLIESSLICH ETELCALCETIDHYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1142 20161111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
